Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Huaiyu Wang
Institutions:
First Affiliated Hospital of Xi'an Jiaotong University,
Xi'an Jiaotong University
Observed institutions:
First Affiliated Hospital of Xi'an Jiaotong University,
First Hospital of Xi'an,
Xi'an Jiaotong University
ORCID:
0000-0002-1350-9709
Observed ORCID:
0000-0002-1350-9709
OpenAlex ID:
A5027023130
An engineered α1β1 integrin-mediated FcγRI signaling component to control enhanced CAR macrophage activation and phagocytosis
2024
·
Fuyu Du
, Zixuan Ye
, et al.
·
Journal of Controlled Release
·
61
PDF
Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications
2025
·
Yan Zhao
, Huaiyu Wang
·
Briefings in Bioinformatics
·
41
PDF
A novel feeder cell based on 4-1BBL and membrane-bound IL-21/IL-15 induce highly expansion and anti-tumor effect of natural killer cells
2025
·
Sha Gong
, Nan Mei
, et al.
·
BMC Biotechnology
·
11
PDF
The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients
2023
·
Xiaoning Wang
, Jie Wang
, et al.
·
Frontiers in Medicine
·
11
PDF
High CX3CR1 expression predicts poor prognosis in paediatric acute myeloid leukaemia undergoing hyperleukocytosis
2022
·
Nan Mei
, Hong Su
, et al.
·
International Journal of Laboratory Hematology
·
6
PDF
Identification of a Prognostic Model Based on NK Cell-Related Genes in Multiple Myeloma Using Single-Cell and Transcriptomic Data Analysis
2024
·
Nan Mei
, Sha Gong
, et al.
·
Blood and Lymphatic Cancer Targets and Therapy
·
4
PDF
Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial
2025
·
Huaiyu Wang
, Xiaohui Wang
, et al.
·
Blood Cancer Journal
·
2
PDF
Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy
2026
·
Lu Wang
, Sha Gong
, et al.
·
Journal for ImmunoTherapy of Cancer
REVO-U: A next-generation, gene-editing–free universal CAR-T platform to enable ultra–high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL.
2026
·
Di Wu
, Sijie Zhao
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
136
H-index:
5
I10-index:
4
Year
Topic
Type